GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The effect of glucagon-like peptide 1 receptor agonists on patients with joint infections was a popular topic at the American ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

These effects were associated with an increase in the expression levels of the GLP-1 receptors (“GLP-1R ... suppression in cynomolgus monkeys. In comparison to a leading oral GLP-1 RA ...

Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

RT-114 combines ProGen's FC fusion protein conjugated GLP-1/GLP-2 dual agonist PG-102 with the RaniPill ... binds to and activates the GLP-1 receptor, mimicking its natural activity.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...